BioNTech (BNTX) Stock Forecast & Price Target

$96.52 +3.40 (+3.65%)

Closing price 04/11/2025 04:00 PM Eastern

Extended Trading

$97.25 +0.73 (+0.76%)

As of 04/11/2025 06:58 PM Eastern

BioNTech - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 18 Analyst Ratings

Sell
0

Hold
3

Buy
15

Based on 18 Wall Street analysts who have issued ratings for BioNTech in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 18 analysts, 3 have given a hold rating, 14 have given a buy rating, and 1 has given a strong buy rating for BNTX.

Consensus Price Target

$143.44
48.61% Upside

According to the 18 analysts' twelve-month price targets for BioNTech, the average price target is $143.44. The highest price target for BNTX is $172.00, while the lowest price target for BNTX is $122.00. The average price target represents a forecasted upside of 48.61% from the current price of $96.52.

Get the Latest News and Ratings for BNTX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for BioNTech and its competitors.

BNTX Analyst Ratings Over Time

Type	Current Forecast 4/13/24 to 4/13/25	1 Month Ago 3/14/24 to 3/14/25	3 Months Ago 1/14/24 to 1/13/25	1 Year Ago 4/14/23 to 4/13/24
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	14 Buy rating(s)	14 Buy rating(s)	13 Buy rating(s)	4 Buy rating(s)
Hold	3 Hold rating(s)	3 Hold rating(s)	3 Hold rating(s)	5 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$143.44	$143.73	$142.72	$120.40
Forecasted Upside	48.61% Upside	44.50% Upside	25.47% Upside	39.22% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Hold

Remove Ads

BNTX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

BNTX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

BioNTech Stock vs. The Competition

Type	BioNTech	Medical Companies	S&P 500
Consensus Rating Score	2.89	2.82	2.54
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	48.61% Upside	21,711.68% Upside	27.84% Upside
News Sentiment Rating	Positive News See Recent BNTX News	Positive News	Positive News

Remove Ads

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
4/1/2025	HC Wainwright 1 of 5 stars	Robert Burns Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$150.00 ➝ $145.00	+59.24%
3/13/2025	Citigroup 2 of 5 stars	Geoff Meacham Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$145.00	+44.55%
3/11/2025	Morgan Stanley 3 of 5 stars	Terence Flynn Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Overweight ➝ Overweight	$145.00 ➝ $139.00	+37.67%
3/11/2025	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	John Newman Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$171.44 ➝ $171.44	+65.58%
3/11/2025	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Etzer Darout Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Outperform ➝ Outperform	$130.00 ➝ $143.00	+35.74%
1/10/2025	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$172.00	+40.81%
12/11/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Bansal Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$170.00	+45.49%
11/26/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$124.00 ➝ $122.00	+1.03%
11/19/2024	Berenberg Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	H. Gillis Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$130.00	+27.61%
11/19/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	C. Kasimov Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	In-Line ➝ Outperform	$110.00 ➝ $125.00	+22.71%
Get the Latest News and Ratings for BNTX and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for BioNTech and its competitors with MarketBeat's FREE daily newsletter.
11/8/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	C. Shibutani Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$90.00 ➝ $137.00	+26.99%
11/5/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Hold ➝ Hold	$132.00 ➝ $122.00	+10.28%
10/7/2024	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$97.00 ➝ $136.00	+10.88%
9/19/2024	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$95.00 ➝ $150.00	+33.87%
9/18/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$97.00 ➝ $131.00	+5.04%
9/17/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy	$96.00 ➝ $150.00	+21.49%
9/16/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$125.00 ➝ $150.00	+23.75%
8/2/2024	Hsbc Global Res Subscribe to MarketBeat All Access for the recommendation accuracy rating	R. Kumar Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
1/5/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Market Perform
5/17/2023	Redburn Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Buy	$165.00 ➝ $170.00	+60.98%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 11:49 AM ET.

Should I Buy BioNTech Stock? BNTX Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, April 7, 2025. Please send any questions or comments about these BioNTech pros and cons to contact@marketbeat.com.

BioNTech
Bull Case

Here are some ways that investors could benefit from investing in BioNTech SE:

Recent earnings per share (EPS) of $1.08 exceeded the consensus estimate of $0.38, indicating strong performance relative to expectations.
Analysts have a positive outlook, with an average price target of $143.73, suggesting potential for stock appreciation.
Institutional investors have shown increased interest, with significant stakes being added, indicating confidence in the company's future.
BioNTech SE is actively developing immunotherapies for cancer and infectious diseases, positioning itself in a growing and essential market.
The current stock price reflects a potential entry point for investors looking to capitalize on future growth opportunities.

BioNTech
Bear Case

Investors should be bearish about investing in BioNTech SE for these reasons:

The company reported a negative return on equity of 2.35% and a negative net margin of 15.16%, indicating challenges in profitability.
Quarterly revenue of $1.19 billion fell short of analysts' expectations of $1.24 billion, reflecting potential operational issues.
Year-over-year revenue decreased by 19.5%, suggesting a decline in business performance compared to the previous year.
Analysts project a negative EPS of -3.88 for the current fiscal year, indicating anticipated losses ahead.
Market volatility and competition in the biotechnology sector could pose risks to BioNTech SE's growth and stock performance.

BNTX Forecast - Frequently Asked Questions

: According to the research reports of 18 Wall Street equities research analysts, the average twelve-month stock price forecast for BioNTech is $143.44, with a high forecast of $172.00 and a low forecast of $122.00.
: 18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioNTech in the last twelve months. There are currently 3 hold ratings, 14 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" BNTX shares.
: According to analysts, BioNTech's stock has a predicted upside of 48.61% based on their 12-month stock forecasts.
: BioNTech has been rated by research analysts at BMO Capital Markets, Canaccord Genuity Group, Citigroup, HC Wainwright, and Morgan Stanley in the past 90 days.
: Analysts like BioNTech more than other "medical" companies. The consensus rating score for BioNTech is 2.89 while the average consensus rating score for "medical" companies is 2.82. Learn more on how BNTX compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NASDAQ:BNTX) was last updated on 4/13/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioNTech (BNTX) Stock Forecast & Price Target